FDA Approves First Immunotherapy for Rare Respiratory Papillomatosis
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba), marking the first approved medical therapy for adults with recurrent respiratory papillomatosis (RRP), a rare …
FDA Approves First Immunotherapy for Rare Respiratory Papillomatosis Read More